Sourcing Exosomes in Oregon
Licensed Oregon practices order Kimera exosome material from ExaVeyra for topical aesthetic use, shipped frozen from Florida with a Certificate of Analysis and lot traceability on every vial. Oregon buyers need their own professional license and NPI; the wholesaler registration is the supplier’s obligation, not the purchaser’s, and Oregon’s lack of a general sales tax means there is no resale certificate to manage.
Oregon pairs two postures found together nowhere else: nurse practitioners hold full practice authority with no physician collaboration requirement, while SB 951, signed in June 2025, gave the state the strictest corporate practice of medicine law in the country. A practice structured around an Oregon management services organization should read that statute before anything else on this page.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Oregon? | Yes. Shipped frozen from Florida, as we do to all 50 states |
| Cold-chain shipping from Florida | Overnight shipping; arrival can take 1 to 3 business days |
| State regenerative-medicine statute | None |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | No |
| Who holds the licensure to ship into the state | The pharmacy partner and the tissue bank that ship, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material. Compounded preparations are not available in this state at this time |
| Last reviewed | 16 October 2026 |
Ordering from Oregon
ExaVeyra ships to licensed practices in all 50 states, Oregon included. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner holds nonresident pharmacy licenses in 33 jurisdictions, including Puerto Rico, and exosome material ships from a registered tissue bank licensed to ship to all 50 states and Puerto Rico. Your practice orders against its own professional license and NPI and needs no wholesale permit to purchase.
What your practice provides
- An active Oregon professional license in good standing, verifiable through the Oregon Medical Board or the Oregon State Board of Nursing license verification services.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed professional-use acknowledgment on file for exosome material.
- No resale certificate: Oregon imposes no general sales or use tax, so the resale documentation other states require for purchase-for-resale has no Oregon equivalent.
How the state permits wholesale distribution
Oregon registers every wholesale distributor shipping into, out of, or within the state as a drug outlet with the Board of Pharmacy under ORS 689.305, in two classes under OAR chapter 855 division 65: Class I covers prescription drugs, and the Board’s own application form is titled for registration in and out of state. An out-of-state Class I applicant shows either a current resident-state wholesale license with verification, or Drug Distributor Accreditation through the National Association of Boards of Pharmacy together with a surety bond naming the Board and a recent inspection report. The registration sits with the distributor, not with the purchasing practice.
ORS 689.305; OAR 855-065-0001, 855-065-0006 · Oregon Board of Pharmacy
Oregon regenerative-medicine law
Oregon has not enacted a statute specific to stem cell or regenerative therapies. Practice in this area is governed by the state's general medical practice and professional licensing rules, alongside federal law.
Oregon has enacted no statute addressing unapproved regenerative therapy: no authorization law of the Florida, Texas, or Georgia kind, no disclosure law of the California kind, and no documentation statute of the Tennessee kind. The legislature considered stem cell research bills twice, HB 2801 in 2007 and HB 2598 in 2009, each proposing a research committee and grant fund, and both died in committee. Practice in this area is therefore governed by the Medical Practice Act in ORS chapter 677, the Nurse Practice Act in ORS chapter 678, and the boards that administer them, alongside federal law, which is the only layer that addresses the products themselves.
How this applies to exosomes
Oregon has no stem cell statute at all, so unlike Florida or Tennessee there is no state definition to ask whether exosomes fall inside. The bills Oregon did consider, in 2007 and 2009, concerned research committees and grant funding rather than clinical practice, and neither passed. Exosomes are acellular extracellular vesicles, and in Oregon they are governed by federal law alone, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with full COA and lot documentation.
Who can handle product in a Oregon practice
Oregon runs on two models. An NP-led practice operates on the nurse practitioner’s own authority under ORS 678.375, with no collaborating physician filing of the Ohio or Georgia kind. A physician-led practice delegates conventionally under the Medical Board’s oversight. What is distinctive is the layer above both: since SB 951, the entity structure itself is regulated, and a management company may not exercise de facto control over clinical operations in either model.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed by the Oregon Medical Board under ORS chapter 677 perform medical acts within their scope and are the source of delegation in a physician-led practice. Under SB 951 a physician’s clinical judgment may not be directed by a management services organization, and noncompetition agreements restricting a medical licensee’s practice are void outside narrow ownership exceptions. |
| NP / APRN | Oregon nurse practitioners are licensed by the Oregon State Board of Nursing under ORS 678.375 and practice independently: they examine patients, diagnose, establish treatment plans, and hold prescriptive authority under ORS 678.390, with no physician collaboration or supervision requirement. An NP-led practice in Oregon evaluates and orders within its own scope. |
| PA | Physician associates practice in collaboration with physicians under the Oregon Medical Board’s framework in ORS chapter 677, within an agreed scope. SB 951 counts physician associates among the medical licensees its ownership and noncompete protections cover. |
| RN | Registered nurses practice under the Nurse Practice Act, ORS chapter 678, and the Oregon State Board of Nursing’s standards, carrying out treatments on the order of a provider with authority to issue one. An RN does not evaluate the patient independently or set the treatment plan. |
Good faith examination
Oregon expects a patient evaluation by a provider with authority to conduct it, and an order, before a delegated treatment is administered. Because nurse practitioners hold full practice authority, that provider can be the NP in an NP-led practice. The expectations sit in board standards rather than a named good faith examination statute, so confirm current requirements with the Oregon Medical Board and the Oregon State Board of Nursing.
Ownership and clinic licensing
Oregon has banned the corporate practice of medicine since a 1947 Oregon Supreme Court decision, and SB 951 (2025) codified the strictest version in the country. Professional corporations practicing medicine must be majority owned and directed by Oregon-licensed physicians under ORS 58.375, or by physicians, physician associates, and nurse practitioners jointly under ORS 58.376. A management services organization and its shareholders, directors, officers, and employees may not own a majority of, control, or exercise de facto control over a professional medical entity they manage, including control over hiring, staffing levels, clinical policies, billing policies, or pricing. The restrictions first apply on 1 January 2026 to MSOs and professional medical entities organized on or after 9 June 2025, and on 1 January 2029 to structures that existed before then. Any Oregon MSO arrangement needs Oregon counsel against the statute’s text.
Cold chain into Oregon
Shipments leave Florida frozen under validated temperature monitoring. A package in transit over a weekend waits in the carrier network, so practices in Oregon order around weekend and holiday closures.
| Metro | County | Notes |
|---|---|---|
| Portland | Multnomah | Largest Oregon market, with broad aesthetic and longevity coverage. |
| Lake Oswego | Clackamas | Affluent south-metro corridor with concentrated med spa coverage. |
| Bend | Deschutes | Central Oregon market with sports medicine and outdoor recovery demand. |
| Eugene | Lane | Southern Willamette Valley hub with a university medical presence. |
| Salem | Marion | Capital market served on the same I-5 lane as Portland. |
| Medford | Jackson | Southern Oregon market serving the California border region. |
- Oregon orders of fifteen or more cold-chain units ship free nationwide; see the volume program for current thresholds.
- Each shipment arrives with the manufacturer’s handling instructions and the lot-specific Certificate of Analysis.
Wholesale exosome supply by city in Oregon
Each city page covers local receiving conditions, delivery disruptions and business license rules for Oregon practices in that area.
Practice types we supply in Oregon
Oregon licensing and verification
Oregon Medical Board
Licenses physicians and physician associates.
Oregon State Board of Nursing
Licenses nurse practitioners, who hold full practice authority in Oregon.
Oregon Board of Pharmacy
Registers the wholesalers that ship drugs into Oregon.
Oregon Department of Revenue
Confirms Oregon has no general sales or use tax, so no resale certificate applies.
Oregon sourcing questions
- Does Oregon have a stem cell law?
- No. Oregon has enacted no stem cell authorization law, disclosure law, or documentation statute. The legislature considered research-committee bills in 2007 and 2009 and neither passed, so there is no Oregon definition that reaches stem cells or exosomes either way. The products are governed by federal law, under which no exosome product is FDA approved for administration to humans.
- What does Oregon SB 951 change for a practice?
- SB 951, signed 9 June 2025, codified the strictest corporate practice of medicine rules in the country. A management services organization and its people may not own a majority of, control, or exercise de facto control over the professional medical entity they manage, including control over hiring, clinical staffing, clinical policies, billing policies, or pricing, and most noncompetition, nondisclosure, and nondisparagement agreements against medical licensees are void. It first applies 1 January 2026 to structures organized on or after 9 June 2025, and 1 January 2029 to pre-existing ones.
- Can a nurse practitioner run a practice in Oregon without a physician?
- Yes, within NP scope. Oregon nurse practitioners are licensed under ORS 678.375 with independent practice and prescriptive authority under ORS 678.390, with no physician collaboration requirement. SB 951 reinforces this from the entity side: nurse practitioners count as medical licensees, and ORS 58.376 lets physicians, physician associates, and nurse practitioners jointly own a professional corporation.
- Does my Oregon clinic need a wholesaler registration to buy exosomes?
- No. The Class I wholesaler registration under ORS 689.305 and OAR chapter 855 division 65 is held by the distributor shipping into Oregon, not by the practice buying. Your practice orders against its own professional license and NPI. Licensure for shipping into the state is held by the entities that ship: our 503A pharmacy partner for compounded preparations, and a registered tissue bank licensed to ship to all 50 states and Puerto Rico for exosome material.
- Does an Oregon practice need a resale certificate to order?
- No. Oregon imposes no general sales or use tax, so the resale certificate item that appears on most states’ ordering checklists has no Oregon equivalent. The Oregon Department of Revenue states this plainly, and ExaVeyra’s account setup for Oregon practices asks only for the professional license, the NPI, and the signed professional-use acknowledgment.
- Are exosomes FDA approved?
- No exosome product has been approved by the FDA for administration to humans, and the FDA has issued a public safety notification about exosome products marketed outside that framework. ExaVeyra supplies Kimera material for topical aesthetic use by licensed practitioners, with a Certificate of Analysis and lot traceability on every vial.
- How long does cold-chain shipping take to Oregon?
- Ships from Florida by overnight shipping, and arrival can take one to three business days. All exosome shipments travel cold-chain with validated temperature monitoring. A shipment in transit over a weekend waits in the carrier network, so a practice that will be closed orders around the closure.
Sources
Last reviewed 16 October 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Oregon SB 951 (2025), enrolled text, Oregon Legislative Information System (accessed 16 October 2026)
- ORS chapter 689, pharmacists and drug outlets, including 689.305 (accessed 16 October 2026)
- Oregon Board of Pharmacy, Wholesaler Class I registration application (accessed 16 October 2026)
- ORS chapter 678, nursing, including nurse practitioner practice and prescriptive authority (accessed 16 October 2026)
- Oregon Department of Revenue, sales tax information (accessed 16 October 2026)
- Oregon Medical Board (accessed 16 October 2026)
- FDA Public Safety Notification on Exosome Products (accessed 16 October 2026)
Scientific literature
Peer-reviewed references, each with its study design and, for human studies, the number of participants, so a reader can judge the weight of a citation without opening it. None is a claim about any product.
- Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 2018. doi:10.1080/20013078.2018.1535750 PMID:30637094Clinical guidelinesupports: The landmark characterization standard for extracellular vesicles, the baseline this page’s documentation discussion assumes when it describes what a defensible exosome COA reports.
- Welsh JA, Goberdhan DCI, O’Driscoll L, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024. doi:10.1002/jev2.12404 PMID:38326288Clinical guidelinesupports: The current revision of the MISEV standard, supporting this page’s point that EV characterization expectations are set by the field’s consensus guidelines rather than by any Oregon statute.
- Lener T, Gimona M, Aigner L, et al. Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper. Journal of Extracellular Vesicles, 2015. doi:10.3402/jev.v4.30087 PMID:26725829Consensus statementsupports: The ISEV position on manufacturing, safety, and regulatory expectations for EV-based products, the context for this page’s statement that no exosome product holds FDA approval.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, and are not tissue products as defined by FDA guidelines.